Actively Recruiting
Studies on the Immunological and Inflammatory Determinants Associated With the Prognosis of Patients Admitted to Intensive Care
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-01-15
540
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
A
Assistance Publique - Hôpitaux de Paris
Lead Sponsor
I
INSERM U942
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are conducting a prospective observational study to understand the immune and inflammatory factors that influence the outcomes of patients admitted to intensive care units (ICU). The goal is to develop models that predict one-year survival and the risk of hospital-acquired infections in these critically ill patients. This study focuses on adults admitted to ICUs for various critical conditions including sepsis, brain injury, major surgery, and polytrauma. Patients in the ICU will have routine biological samples collected as part of their care, with additional minimal blood samples taken specifically for this study to analyze immune and inflammatory markers. Sampling will occur at admission, day 1, day 4, day 8, ICU discharge or day 28, and again at 12 months. Extra samples may be collected if significant clinical events like infections or complications occur during the ICU stay. Participants will be monitored through blood tests and flow cytometry to profile immune cells and inflammatory status over time. Researchers will also assess survival at 12 months and changes in organ failure scores during the first week. Molecular analyses such as transcriptomic profiling of immune cells will help understand changes from baseline to one year. The study involves no treatment intervention and will follow patients for a full year to gather comprehensive data on their immune response and outcomes after critical illness.
CONDITIONS
Brief Title
IMMUNOREA - Immunological and Inflammatory Determinants Associated With the Prognosis of Intensive Care Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 65 18 years
- Admission to ICU within 24 hours
You will not qualify if you...
- Moribund patient (ECOG=4)
- Legal protection (guardianship/curatorship)
- Uninsured patients
- Pre-existing immunosuppression (active/recent cancer, hematologic disease, autoimmune disease, organ transplant, HIV)
- Pregnant or breastfeeding women
- Participation in another interventional trial
- Patients under AME
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months
Participants admitted to intensive care are observed to study immunological and inflammatory determinants over time.
Visits occur from baseline up to 12 months with assessments including blood profiling and clinical scoring
Trial Site Locations
Total: 1 location
1
AP-HP Laribosière Hospital, Anesthesia and Critical Care Departement
Paris, France, 75010
Actively Recruiting
Research Team
C
Charles de de Roquetaillade, MD
B
Benjamin Glenn Chousterman, MD PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here